EUVIMEDEUVIMED entdecken
MetaanalyseVergleichsstudie

Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety

Mahmoud Kandeel, Mohamed A Morsy, Khalid M Alkhodair, Sameer Alhojaily

Inflammopharmacology · 2024

DOI: 10.1007/s10787-024-01563-3 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Mahmoud Kandeel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, 31982, Al-Ahsa, Saudi Arabia. mkandeel@kfu.edu.sa. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Janus Kinase Inhibitors, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: King Salman Center for Disability Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder characterized by persistent inflammation leading to progressively worse disability. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF) inhibitors are pivotal in RA treatment, yet their comparative efficacy remains underexplored. AIM: This study aimed to compare the efficacy and safety of JAK inhibitors and TNF inhibitors in treating RA using data from randomized controlled trials (RCTs). METHODS: A meta-analysis and outcomes analysis were based on results of the Health Assessment Questionnaire Disability Index (HAQ-DI), Clinical Disease Activity Index (CDAI), Visual Analogue Scale (VAS), and Patient Global Assessment Scale (PtGA) and other indices as incidences of venous thromboembolism (VTE) and malignancy. RESULTS: The JAK inhibitors caused a statistically significant improvement in the HAQ-DI score [MD = 0.08, 95% CI (0.03, 0.12), p = 0.0008] compared with the TNF inhibitors. However, no significant difference was observed between the two drug classes in the CDAI score [MD = - 2.03, 95% CI (- 9.27, 5.22), p = 0.58]. JAK inhibitors were associated with an increase in the VAS score [MD = 3.62, 95% CI (0.86, 6.38), p = 0.01], but there was no significant difference in the PtGA score [MD = 1.91, 95% CI (- 3.25, 7.08), p = 0.47]. CONCLUSION: JAK inhibitors demonstrated superior efficacy in improving the functional status and reducing the disease activity in RA patients compared with TNF inhibitors. Both drug classes exhibited comparable safety profiles for VTE and malignancies, though JAK inhibitors had a higher risk for thromboembolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidJanus Kinase InhibitorsTumor Necrosis Factor InhibitorsHumansRandomized Controlled Trials as TopicTreatment OutcomeVenous Thromboembolism

Stichwörter der Autor:innen

EfficacyJAK inhibitorsMeta-analysisRandomized controlled trialsRheumatoid arthritisSafetyTNF inhibitors

Substanzen

Antirheumatic AgentsJanus Kinase InhibitorsTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, 31982, Al-Ahsa, Saudi Arabia. mkandeel@kfu.edu.sa.
  • Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, 33516, Egypt. mkandeel@kfu.edu.sa.
  • Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, 31982, Al-Ahsa, Saudi Arabia.
  • Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, 61511, Egypt.
  • Department of Anatomy, College of Veterinary Medicine, King Faisal University, 31982, Al-Ahsa, Saudi Arabia.
  • Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, 31982, Al-Ahsa, Saudi Arabia.

Förderung

  • King Salman Center for Disability Research

Zitieren

APA

Kandeel, M., Morsy, M. A., Alkhodair, K. M., & Alhojaily, S. (2024). Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01563-3

Vancouver

Kandeel M, Morsy MA, Alkhodair KM, Alhojaily S. Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01563-3

BibTeX
@article{Kandeel2024,
  author = {Kandeel, Mahmoud and Morsy, Mohamed A and Alkhodair, Khalid M and Alhojaily, Sameer},
  title = {Janus kinase inhibitors versus tumor necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety},
  journal = {Inflammopharmacology},
  year = {2024},
  doi = {10.1007/s10787-024-01563-3}
}
Kostenlos starten →